Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure. 1989

T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
Hôpital Necker, Paris, France.

Administration of recombinant erythropoietin constitutes a revolution in treatment of the anemia of chronic dialysis patients. Such treatment has been anxiously awaited. Its realization has been possible thanks to the spectacular progress allowed by the newly developed techniques of recombinant genetics. Correction of this type of anemia can be obtained rapidly and permanently if treatment is continued without interruption. It is followed by a remarkable transformation of the patient's physical and psychic status. The occurrence of certain side effects (e.g., elevation of blood pressure and an increased tendency toward vascular thrombosis), however, requires increased awareness in the follow-up of patients at risk and adaptation of erythropoietin administration to individual needs.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
January 1991, Child nephrology and urology,
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
January 1995, Duodecim; laaketieteellinen aikakauskirja,
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
August 1987, Experimental hematology,
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
January 2006, Seminars in dialysis,
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
June 1988, American family physician,
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
March 1997, Kidney international,
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
January 1990, Annual review of medicine,
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
July 1987, The New England journal of medicine,
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
November 1993, Acta paediatrica (Oslo, Norway : 1992),
T Drüeke, and B Zins, and C Naret, and N Casadevall, and Y Goureau, and L Bererhi, and F Peterlongo, and J P Castaigne, and J Zingraff, and S Delons
October 1990, The American journal of medicine,
Copied contents to your clipboard!